| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,140 | 0,151 | 29.10. |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 22.09. | VIVA BIOTECH (01873): INTERIM REPORT 2026 | 3 | HKEx | ||
| VIVA BIOTECH Aktie jetzt für 0€ handeln | |||||
| 26.08. | Viva Biotech Announces Its 2026 Interim Results: AI Sparks New Paradigm in Drug R&D, CDMO Commercial Manufacturing Accelerates Revenue Growth | 300 | PR Newswire | Results Highlights for Interim Results ended 30 June 2026Revenue reached RMB1,006.5 million, increasing by 21.0% YoYGross profit amounted to RMB341.7 million, increasing... ► Artikel lesen | |
| 26.08. | Viva Biotech Holdings Announces Decline In H1 Profit | 1 | RTTNews | ||
| 26.08. | VIVA BIOTECH (01873): INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2026 | 1 | HKEx | ||
| 14.08. | VIVA BIOTECH (01873): DATE OF BOARD MEETING | 2 | HKEx | ||
| 14.07. | VIVA BIOTECH (01873): NEXT DAY DISCLOSURE RETURN | 2 | HKEx | ||
| 26.06. | VIVA BIOTECH (01873): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JUNE 26, 2026 | 1 | HKEx | ||
| 25.06. | VIVA BIOTECH (01873): VOLUNTARY ANNOUNCEMENT GRANT OF RESTRICTED SHARE UNITS | - | HKEx | ||
| 25.06. | VIVA BIOTECH (01873): NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
| 18.06. | VIVA BIOTECH (01873): NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
| 10.06. | VIVA BIOTECH (01873): NEXT DAY DISCLOSURE RETURN | 2 | HKEx | ||
| 03.06. | VIVA BIOTECH (01873): NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
| 27.05. | Viva Biotech: From Hit Identification to Lead Optimization: Building Scientific Continuity in Early Drug Discovery | 827 | PR Newswire | SHANGHAI, May 27, 2026 /PRNewswire/ -- On May 20, 2026, Viva Biotech hosted a V-Experts in Conversation webinar, "Managing Complexity in Modern Drug Discovery: A Practical Approach to Integrated... ► Artikel lesen | |
| 26.05. | VIVA BIOTECH (01873): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| 18.05. | VIVA BIOTECH (01873): NEXT DAY DISCLOSURE RETURN | 4 | HKEx | ||
| 08.05. | VIVA BIOTECH (01873): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| 17.03. | Viva Biotech Accelerates AI-Driven Drug Discovery and Advance the 'Lab-in-the-Loop' with NVIDIA | 760 | PR Newswire | SHANGHAI, March 17, 2026 /PRNewswire/ -- Monday, March 16th at 1:30 PM PT, Viva Biotech (01873.HK) optimizes the Proteina-Complexa model in advancing the design of mini-binders targeting... ► Artikel lesen | |
| 29.12.25 | Adventures in DMPK: Viva Biotech's One-Stop Pharmacology Platform Cross New Modalities | 590 | PR Newswire | SHANGHAI, Dec. 29, 2025 /PRNewswire/ -- Drug Pharmacokinetics and Pharmacodynamics (PKPD) has become increasingly critical as drug discovery modalities continue to expand across a broader... ► Artikel lesen | |
| 15.12.25 | Viva Biotech's invested and incubated company, Arthrosi, has entered into an acquisition agreement with Sobi for a total transaction value of up to US$1.5 billion. | 557 | PR Newswire | STOCKHOLM, Dec. 15, 2025 /PRNewswire/ -- Swedish Orphan Biovitrum AB (STO: SOBI) recently announced that it has entered into an acquisition agreement with Arthrosi Therapeutics, Inc., which... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VALNEVA | 2,540 | -0,59 % | Valneva bekommt eine 3-: Warum unsere Experten so vorsichtig urteilen - Mein Rat: sofort handeln! | ||
| NOVONESIS | 62,12 | +0,03 % | Novonesis (Novozymes A/S): Transactions under Novonesis' share buyback program | ||
| GENMAB | 505,80 | +0,16 % | Genmab-Aktie: Wie weit geht diese Kursrallye noch? | Die Genmab-Aktie schoss am gestrigen Montag um +12% nach oben und kletterte damit auf den höchsten Stand seit über drei Jahren. Was treibt den Kurs des dänischen Biotech-Unternehmens unaufhörlich nach... ► Artikel lesen | |
| ARBUTUS BIOPHARMA | 3,840 | 0,00 % | Arbutus Biopharma: FDA hebt klinischen Stopp für AB-101 auf - Aktie legt vorbörslich zu | ||
| BEONE MEDICINES LTD ADR | 334,00 | 0,00 % | BeOne Medicines Ltd.: BeOne präsentiert auf der ESMO 2026 überzeugende Daten zu schwer zu behandelndem Leber- und Lungenkrebs | Potenziell erster bispezifischer GPC3 x 4-1BB Antikörper seiner Klasse erzielt bei der Phase-3-Dosis eine bestätigte Ansprechrate von 36 und zeigt ein günstiges Sicherheitsprofil bei stark vorbehandeltem... ► Artikel lesen | |
| MUSTGROW BIOLOGICS | 0,250 | 0,00 % | Satte Kursgewinne mit der grünen Transformation! Wie Coca-Cola, Bayer, MustGrow und PepsiCo an die Zukunft denken | Erstellt und veröffentlicht im Auftrag von MustGrow Biologics Corp. Trotz regulatorischer Fortschritte bleibt die Welternährungslage extrem prekär. Laut einem aktuellen Bericht der Welthungerhilfe und... ► Artikel lesen | |
| SINO BIOPHARM | 0,543 | -0,89 % | SBP GROUP Two Hepatitis B New Drugs Included in Breakthrough Therapy Designation Program | ||
| VERICEL | 35,800 | -6,77 % | Vericel Corporation: Vericel Reports Second Quarter 2026 Financial Results, Raises Full-Year Financial Guidance and Announces Share Repurchase Program | Total Revenue Increased 22% to $77.5 Million, with MACI Revenue Growth of 23% Net Income of $2.2 Million and Free Cash Flow of $14.3 Million Full-Year 2026 Revenue Guidance Raised to $330 to $340... ► Artikel lesen | |
| MOLECULIN BIOTECH | 7,600 | -15,50 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.10.2026 -4- | The following instruments on Boerse Frankfurt do have their last trading day on 02.10.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.10.2026ISIN NameUS1509643029 CENNTRO... ► Artikel lesen | |
| FAETH THERAPEUTICS | 16,700 | 0,00 % | Faeth Therapeutics: Faeth Presents Updated Preclinical Data at ESMO, including First-Ever Head-to-Head Characterization of PIKTOR against Gedatolisib | In two preclinical breast cancer xenograft models (abstract #431P), PIKTOR inhibited tumor growth to a comparable or greater extent than intravenous gedatolisibPIKTOR inhibited HR+/HER2- breast cancer... ► Artikel lesen | |
| ZAI LAB LTD ADR | 20,400 | +2,00 % | Zai Lab Limited: Zai Lab's Zocilurtatug Pelitecan (Zoci, Formerly ZL-1310) Demonstrates High Response Rates, Encouraging Durability and Well-Tolerated Safety Profile in First-Line Extensive-Stage Small Cell Lung Cancer | At the recommended Phase 3 dose (RP3D) of 1.6 mg/kg, zoci plus atezolizumab achieved a confirmed objective response rate of 81.8% (27/33) and an estimated 6-month progression-free survival rate... ► Artikel lesen | |
| BIOXCEL THERAPEUTICS | 0,065 | 0,00 % | Teva Completes Acquisition of BioXcel Assets, Expands Neuroscience Pipeline | ||
| REGENXBIO | 6,534 | -1,77 % | XFRA RB0: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| QIAGEN | 45,050 | -0,11 % | Bye, bye Börse: Delisting: DAX-Aktie Qiagen wird wohl bald verschwinden | © Foto: Andreas Arnold/dpaDer Private-Equity-Riese EQT will Qiagen übernehmen. Experten trauen dem Angebot den Durchbruch zu. Der Diagnostik-Konzern dürfte anschließend von der Börse genommen werden.... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 288,62 | 0,00 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen |